Oral / Intravenous · GLP-1 agonist

NNC0113-0987

5 trials in this molecule. Source: ClinicalTrials.gov, as of November 5, 2026.

Trials

Ongoing

Recruiting

Completed

Sites

Countries

Endpoints

Composite endpoints

Distinct sites and countries across this molecule's trials. A site running several of its trials counts once, matching the map.

Where the program stands

Trials by phase

Phase 1

Trials by status

Completed

Evidence coverage

Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.

Safety / tolerability / PK

Glycemic / diabetes

Weight & body composition

Every trial for this molecule, with the same search, filters, and sort as the Trials tab.

⌘K

5 of 5

GLP-1 and incretin trials
	Asset / Population	Eligibility highlight
NCT01405261Trial Investigating the Safety of NNC 0113-0987 in Healthy Male Subjects	NNC0113-0987 Healthy volunteers, Type 2 diabetes	BMI ≤30	Ph 1	Completed	1	May 2012	-
NCT01978613Investigation on Safety, Tolerability and Pharmacokinetics of Multiple Doses of NNC0113-0987 in an Oral Formulation in Healthy Subjects	NNC0113-0987 Diabetes (other / unspecified), Healthy volunteers	BMI 20-29.9	Ph 1	Completed	1	Jun 2014	-
NCT02094521Evaluation of Optimal Dosing Conditions for GLP-1 Analogue NNC0113-0987 When Administered Orally in Healthy Male Subjects	NNC0113-0987 Diabetes (other / unspecified), Healthy volunteers	BMI 18.5-29.9	Ph 1	Completed	1	Jul 2014	-
NCT01967589Investigation on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of a Long Acting GLP-1 Analogue (NNC0113-0987) in Healthy Male Subjects	NNC0113-0987 Diabetes (other / unspecified), Healthy volunteers	BMI 20-29.9	Ph 1	Completed	1	May 2014	-
NCT01690169Investigation on Safety, Tolerability, and Pharmacokinetics of Single Doses of NNC0113-0987 in Healthy Male Subjects	NNC0113-0987 Healthy volunteers, Type 2 diabetes	BMI ≤30	Ph 1	Completed	1	Dec 2012	-

Showing 1-5 of 5 trials